These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 2957187)

  • 41. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
    Johnson AP; Uttley AH; Woodford N; George RC
    Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Technical factors influencing the bactericidal activity of teicoplanin against staphylococci.
    Pasticci MB; Moretti A; Frongillo RF; Baldelli F; Moretti MV; Pauluzzi S
    Boll Ist Sieroter Milan; 1989; 68(2):101-7. PubMed ID: 2535247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
    Biavasco F; Lupidi R; Varaldo PE
    Antimicrob Agents Chemother; 1992 Feb; 36(2):331-8. PubMed ID: 1534977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously.
    Van der Auwera P; Klastersky J
    J Antimicrob Chemother; 1987 May; 19(5):623-35. PubMed ID: 2956228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antistaphylococcal and antienterococcal activity of the new teicoplanin amide derivative MDL 62873.
    Qadri SM; Saldin H; Ueno Y
    Chemotherapy; 1993; 39(1):55-8. PubMed ID: 8444061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.
    Cynamon MH; Granato PA
    Antimicrob Agents Chemother; 1982 Mar; 21(3):504-5. PubMed ID: 6213192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria.
    Hassan H; O'Hare MD; Felmingham D
    Singapore Med J; 1990 Feb; 31(1):56-8. PubMed ID: 2139737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro antimicrobial activity of the thiazolyl peptide antibiotic MDL 62,879 (GE2270 A).
    Kenny MT; Brackman MA; Dulworth JK
    Chemotherapy; 1997; 43(4):254-63. PubMed ID: 9209782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin.
    Greenwood D; Bidgood K; Turner M
    J Antimicrob Chemother; 1987 Aug; 20(2):155-64. PubMed ID: 2959642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of teicoplanin compared with vancomycin alone, and combined with gentamicin, against penicillin tolerant viridans streptococci and enterococci causing endocarditis.
    Shanson DC; Tadayon M
    J Hosp Infect; 1986 Mar; 7 Suppl A():65-72. PubMed ID: 2871099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin.
    Urban C; Mariano N; Mosinka-Snipas K; Wadee C; Chahrour T; Rahal JJ
    J Antimicrob Chemother; 1996 Feb; 37(2):361-4. PubMed ID: 8707748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
    Rolston KV; Nguyen H; Messer M
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2137-41. PubMed ID: 2149921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of teichomycin against isolates of gram-positive bacteria.
    Fietta A; Bersani C; Mangiarotti P; Gialdroni Grassi G
    Chemotherapy; 1983; 29(4):275-82. PubMed ID: 6223793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.
    Berti M; Candiani G; Borgonovi M; Landini P; Ripamonti F; Scotti R; Cavenaghi L; Denaro M; Goldstein BP
    Antimicrob Agents Chemother; 1992 Feb; 36(2):446-52. PubMed ID: 1534978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity and human pharmacokinetics of teicoplanin.
    Verbist L; Tjandramaga B; Hendrickx B; Van Hecken A; Van Melle P; Verbesselt R; Verhaegen J; De Schepper PJ
    Antimicrob Agents Chemother; 1984 Dec; 26(6):881-6. PubMed ID: 6240962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.
    Bailey EM; Rybak MJ; Kaatz GW
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1089-92. PubMed ID: 1834010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.